Trial Profile
Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2012
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis; Hyperlipidaemia; Systemic lupus erythematosus
- Focus Biomarker; Pharmacodynamics
- Sponsors AstraZeneca
- 11 Jan 2012 New trial record